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http://djournal homepage: www.elsevier.com/locate/lrrLetter to the EditorFig. 1. Photomicrograph of the bone marrow trephine biopsy showing gelatinous
transformation. Alcian blue pH 2.5; 400 .Gelatinous transformation of bone marrow following the use
of dasatinib in a patient with philadelphia chromosome-
positive acute lymphoblastic leukemia
Gelatinous transformation of bone marrow (GTBM) is a rare
disorder characterized by loss of adipose and hematopoietic
tissues, and deposition of extracellular gelatinous mucopolysac-
charides, particularly hyaluronic acid.1,2 The common causes of
gelatinous transformation of bone marrow are anorexia nervosa,
acquired immunodeﬁciency syndrome, alcoholism, carcinomas,
leukemias, lymphomas and chemotherapeutic agents.1–5 Imatinib
has been reported to cause gelatinous transformation of bone
marrow in patients with chronic myeloid leukemia and philadel-
phia chromosome-positive acute lymphoblastic leukemia (Phþ
ALL).6–8 We report here a case of Phþ ALL who was treated with
dasatinib, following which he developed gelatinous transforma-
tion of bone marrow.
An 18-years-old male was admitted with the complaints of
generalized weakness and fever for one month duration. On
examination he had pallor with cervical lymphadenopathy and
hepatosplenomegaly. Hemogram revealed hemoglobin 5.5 g/dl,
total leukocyte count 130109/l, platelet count 40109/l with
peripheral blood smear showing 85% blasts, morphologically
lymphoid. Bone marrow examination conﬁrmed the replacement
of marrow by lymphoid blasts. On immunophenotyping the blasts
were positive for CD34, HLA-DR, CD19, CD20 and cCD79a.
Qualitative polymerase chain reaction (PCR) for BCR-ABL was
positive. Cerebrospinal ﬂuid examination also revealed the pre-
sence of blasts. His viral studies were negative for HBsAg, anti-
HCV and HIV. He was started on supportive treatment with
intravenous ﬂuids, allopurinol and BFM-95 induction chemother-
apy (prednisolone 60 mg/m2 from day 1 and vincristine 1.5 mg/
m2 and daunorubicin 30 mg/m2 from day 8) alongwith dasatinib
50 mg twice daily from day 1. Intrathecal chemotherapy included
methotrexate 12.5 mg twice weekly. Patient developed pancyto-
penia with febrile neutropenia on day 10 and was started on
intravenous antibiotics as per institutional policy. Blood and urine
cultures were negative for bacteria and fungi. Computed tomo-
graphy of chest was normal. He was continued on supportive
treatment. Peripheral blood smear on day 8 did not show any
blasts. Because of persistent fever, amphotericin (1 mg/kg) was
added along-with granulocyte-colony stimulating factor (G-CSF).
Fever continued and patient had persistent cytopenias (total
leukocyte count 0.2109/l, absolute neutrophil count
0.05109/l and platelet count 10109/l). Bone marrow exam-
ination was repeated on day 32 and it showed serous degenera-
tion of marrow with increased extracellular matrix, loss of fat
cells and gelatinous transformation, conﬁrmed with Alcian blue
staining (Fig. 1). The overall cellularity of the bone marrow was
5–10%.
Normally, gelatinous material is not found in the bone marrow
and therefore, its presence signiﬁes a pathological event.89 & 2012 Elsevier Ltd.
x.doi.org/10.1016/j.lrr.2012.11.004
Open access under CC BY-NC-ND license.Chemotherapeutic drugs, including melphalan and imatinib, have
been implicated in the causation of GTBM.6–10 There is usually
complete recovery of marrow following initial gelatinous trans-
formation in the patients receiving chemotherapy for acute
leukemia,1 but our case showed no marrow recovery. Moreover,
GTBM associated with chemotherapy is characterized by absence
of fat atrophy and is often transient.1 Our patient had evidence of
fat atrophy along-with gelatinous transformation. GTBM may
respond to hematopoietic growth factors 9 but our patient did
not have any response to G-CSF and succumbed to febrile
neutropenia.
The mechanism leading to the gelatinous transformation may
involve inhibition of tyrosine kinase activity by tyrosine kinase
inhibitors (TKI) leading to blockage of downstream signal path-
ways, affecting extracellular matrix deposition, adipocyte differ-
entiation and angiogenesis.10–13 Moreover, the catabolic
processes in leukemia may also lead to the production of
hyaluronic acid by leukemic cells.1,5 Dasatinib, a more potent
second generation TKI, has been used for treatment of chronic
myeloid leukemia as well as Phþ ALL. It can cause cytopenias but
gelatinous transformation is an unusual event. Though our
patient also received prednisolone, vincristine, daunorubicin and
asparaginase as a part of induction therapy for ALL alongwith
dasatinib, we conclude that the gelatinous transformation and
non-recovery of marrow probably was due to dasatinib, analo-
gous to that caused by imatinib as reported in previous stu-
dies.6,7,10 Pancytopenia can develop following treatment with
TKIs 5,7,9,14 and bone marrow examination may be required for
deﬁnitive diagnosis.
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